Summary: PathAI launches AIM-HI UC and IBDExplore

Why It Matters: PathAI is expanding its clinical trial tools to target specific diseases like Ulcerative Colitis and Inflammatory Bowel Disease. This shows they are moving deeper into specialized drug testing markets.

What Changed:

• Added a new press release about the launch of AIM-HI UC and IBDExplore for clinical trials.
• Added a new section for "Anatomic Pathology" that highlights the AISight platform and Precision Pathology Network.
• Updated the BioPharma section with a direct link to laboratory services.
• Reorganized the news feed to prioritize the February 2026 announcement.